Lehman Courtney, Peebles Ray Stokes
Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Explor Asthma Allergy. 2025;3. doi: 10.37349/eaa.2025.100967. Epub 2024 Dec 17.
Glucagon-like peptide-1 (GLP-1) is a hormone that regulates blood glucose levels and is produced by the enteroendocrine glands in the large and small intestines in response to the consumption of foods that contain carbohydrates, fats, and proteins. When GLP-1 is secreted, it acts on the pancreas to increase insulin production and secretion, while decreasing pancreatic glucagon secretion in order to lower serum glucose. However, GLP-1 also regulates metabolism through the gut-brain axis. While GLP-1 is primarily produced in the gut and released into the bloodstream, small quantities of it can also be synthesized in distinct areas of neurons located in the hindbrain. Recent studies have proposed that GLP-1 receptor (GLP-1R) agonists (GLP-1RAs) may protect against neuroinflammatory diseases. GLP-1RAs may also be a therapeutic target for asthma as animal models show that these drugs reduce allergen-induced airway inflammation, as the GLP-1R is expressed on lung epithelial and endothelial cells. There is a notable association between insulin resistance and the onset of asthma, particularly among obese people, with this association suggesting that metabolic dysfunction may play a role in asthma development. There is also evidence that there may be a link between asthma pathobiology and neuroinflammation, suggesting that GLP-1 and its analogs may regulate neuroinflammatory pathways that contribute to asthma pathogenesis. Interest is growing, though research remains limited, in how inflammation in the nervous system and lung might be linked. This review will explore how GLP-1R signaling could inhibit interdependent inflammation in both the lung and nervous system. This review will first focus on the inflammation that is known to exist in asthma, then pivot to the current state of neural regulation of asthma, and finally speculate on how GLP-1RA signaling could inhibit both neural and lung inflammation in asthma treatment.
胰高血糖素样肽-1(GLP-1)是一种调节血糖水平的激素,由大小肠中的肠内分泌腺在摄入含有碳水化合物、脂肪和蛋白质的食物后产生。当GLP-1分泌时,它作用于胰腺以增加胰岛素的产生和分泌,同时减少胰腺胰高血糖素的分泌以降低血糖。然而,GLP-1也通过肠-脑轴调节新陈代谢。虽然GLP-1主要在肠道产生并释放到血液中,但在位于后脑的不同神经元区域也能合成少量的GLP-1。最近的研究表明,GLP-1受体(GLP-1R)激动剂(GLP-1RAs)可能对神经炎症性疾病具有保护作用。GLP-1RAs也可能是哮喘的治疗靶点,因为动物模型显示这些药物可减轻过敏原诱导的气道炎症,因为GLP-1R在肺上皮细胞和内皮细胞上表达。胰岛素抵抗与哮喘的发病之间存在显著关联,尤其是在肥胖人群中,这种关联表明代谢功能障碍可能在哮喘的发展中起作用。也有证据表明哮喘病理生物学与神经炎症之间可能存在联系,这表明GLP-1及其类似物可能调节导致哮喘发病机制的神经炎症途径。尽管研究仍然有限,但人们对神经系统和肺部炎症之间可能存在的联系的兴趣正在增加。本综述将探讨GLP-1R信号传导如何抑制肺和神经系统中的相互依存炎症。本综述将首先关注已知存在于哮喘中的炎症,然后转向哮喘神经调节的现状,最后推测GLP-1RA信号传导在哮喘治疗中如何抑制神经和肺部炎症。